Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Tyra Biosciences is a clinical-stage biotech focused on developing precision medicines targeting FGFR biology for oncology and genetically defined conditions. Its in-house SNÅP platform enables rapid, selective drug design. Core programs include FGFR3 inhibitors for bladder cancer and skeletal disorders, FGFR2 inhibitors for cholangiocarcinoma, and FGFR4/3 inhibitors for hepatocellular carcinoma, aiming to address unmet medical needs with innovative, targeted therapies.
This description was generated via AI from an annual report. Updated about 1 year ago.